Multiple sclerosis and cognitive impairment
Clinical research activity in multiple sclerosis includes interest in cognitive deficits and resting-state fMRI markers linked to treatment response. The sponsor is involved in work examining modafinil in relation to cognition and brain activity patterns.
- Modafinil response prediction
- Resting-state fMRI
- Cognitive deficits
These studies place neurology and neuroimaging at the center of the sponsor’s research portfolio.
Obsessive-compulsive disorder and psychiatric treatment resistance
The sponsor funds research in obsessive-compulsive disorder focused on resistant OCD and augmentation strategies for SSRI treatment. Interest is directed toward pramipexole as an adjunctive psychiatric intervention.
- Resistant OCD
- SSRI augmentation
- Pramipexole
This area reflects engagement with psychiatry and anxiety-related disorders.
Benign prostatic hyperplasia and lower urinary tract symptoms
In urology, the sponsor supports studies on benign prostatic hyperplasia and associated lower urinary tract symptoms, with attention to symptom burden measured through IPSS. The research includes evaluation of tryptophan supplementation in men with established disease.
- Benign prostatic hyperplasia
- Lower urinary tract symptoms
- Tryptophan supplementation
These trials connect the sponsor with prostate health and urinary symptom management.
Neuropsychiatric and symptom-focused translational research
The funded studies span neurology, psychiatry, and urology, with a common interest in identifying treatment-responsive patient groups and clinically meaningful symptom changes. The sponsor’s portfolio includes work on brain-based biomarkers, adjunctive psychiatric therapy, and symptom relief in chronic urologic disease.
- Biomarker-oriented research
- Adjunctive therapy
- Symptom assessment
The clinical landscape is concentrated in Portugal, with all active studies conducted through a single collaborating research site in Braga.
